EU Commission President Unveils Ambitious 2025 Biotech Act to Boost European Life Sciences
Key Insights
European Commission President Ursula von der Leyen announces plans for a new European Biotech Act in 2025, aimed at simplifying regulations and improving financing access for biotech companies.
The initiative includes establishment of an EU biotech hub and European Savings and Investments Union to strengthen capital markets and support innovative life science projects.
Von der Leyen's re-election platform emphasizes frontier technologies investment, including genomics and AI integration in healthcare, with plans for AI Factories and a dedicated Research Council.
Re-elected European Commission President Ursula von der Leyen has unveiled ambitious plans to revolutionize the European biotech landscape through a comprehensive new European Biotech Act set to launch in 2025. The initiative aims to address key challenges facing the life sciences sector, particularly regulatory complexity and funding accessibility.
The proposed legislation represents a significant shift in the EU's approach to biotech development, focusing on streamlining regulations that have historically deterred investment in the region. A central component of the plan is ensuring European biotech companies can secure funding within the EU rather than seeking capital in the US or Asia.
"Biotechnology is rightfully recognised by President von der Leyen as central to Europe's future," stated Dr. Claire Skentelbery, EuropaBio (search)'s Director General, emphasizing the sector's importance to EU economic strength and resilience.
Strategic Infrastructure Development
The Commission's strategy includes the imminent launch of an EU biotech hub, scheduled to begin operations by year-end. This facility will serve as a central resource for biotech companies navigating existing regulations and accessing support services.
To address capital market challenges, the initiative introduces a European Savings and Investments Union, designed to consolidate the EU's fragmented capital markets. This structure aims to simplify investment processes for both institutional and retail investors interested in supporting innovative biotech projects.
Expanding Technology Integration
The comprehensive plan extends beyond traditional biotech, encompassing various frontier technologies including:
- Genomics advancement
- Supercomputing capabilities
- Quantum computing development
- Internet of Things integration
AI Integration in Healthcare
Von der Leyen's vision includes significant artificial intelligence initiatives specifically targeting healthcare advancement. Key elements include:
- Creation of AI Factories providing startups access to essential computing infrastructure
- Establishment of an AI Research Council modeled after CERN
- Development of a comprehensive AI strategy focusing on healthcare service delivery optimization
Capital Access Enhancement
The initiative introduces measures to facilitate financing through:
- Streamlined processes for commercial banks and venture capital firms
- Expansion of the European Innovation Council
- Simplified regulatory frameworks for scaling research discoveries to market
Clark Parsons, European Start-up Network (search) CEO, while welcoming these developments, emphasized the need for additional reforms: "Besides much-needed capital, Europe's start-ups need fast access to new markets, which means we have to enable start-up roaming, legal passports, call it what you will. Setting up 27 different companies for one 'single market' is not working."
The measures received strong parliamentary support, with von der Leyen securing 401 votes in favor versus 284 against in the 720-member European Parliament ballot, demonstrating substantial backing for her biotech and innovation agenda.